Thymic carcinoma future or investigational therapies

Jump to navigation Jump to search

Thymic Carcinoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymic carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Thymic carcinoma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Thymic carcinoma future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymic carcinoma future or investigational therapies

CDC on Thymic carcinoma future or investigational therapies

Thymic carcinoma future or investigational therapies in the news

Blogs on Thymic carcinoma future or investigational therapies

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Thymic carcinoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

Due to the advancement in understanding the molecular biology of the disease, there is an increased number of targeted therapies being tested in clinical trials, but the results have so far been disappointing.

Targeted Therapy

  • KIT pathway

It is overexpressed by immunohistochemistry in 79% of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.[1]

  • Epidermal growth factor pathway

It is overexpressed by immunohistochemistry in 53% of thymic carcinomas. Cetuximab, erlotinib, gefitinib are being used in different clinical trials.[2]

  • IGF-1R pathway

Expression of IGF-1R was found in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in ndifferent clinical trials.[3]

References

  1. ↑ Ströbel, P.; Hartmann, M.; Jakob, A.; Mikesch, K.; Brink, I.; Dirnhofer, S.; Marx, A. (2004). "Thymic carcinoma with overexpression of mutated KIT and the response to imatinib". N Engl J Med. 350 (25): 2625–6. doi:10.1056/NEJM200406173502523. PMID 15201427. Unknown parameter |month= ignored (help)
  2. ↑ Farina, G.; Garassino, MC.; Gambacorta, M.; La Verde, N.; Gherardi, G.; Scanni, A. (2007). "Response of thymoma to cetuximab". Lancet Oncol. 8 (5): 449–50. doi:10.1016/S1470-2045(07)70141-9. PMID 17466903. Unknown parameter |month= ignored (help)
  3. ↑ Kelly, RJ.; Petrini, I.; Rajan, A.; Wang, Y.; Giaccone, G. (2011). "Thymic malignancies: from clinical management to targeted therapies". J Clin Oncol. 29 (36): 4820–7. doi:10.1200/JCO.2011.36.0487. PMID 22105817. Unknown parameter |month= ignored (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Thymic_carcinoma_future_or_investigational_therapies&oldid=1397331"